
MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms

Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD). In addition, MagVenture TMS Therapy® can reduce the symptoms of comorbid anxiety in patients suffering from depression. These new approvals will expand the treatment options of MagVenture TMS Therapy® considerably, which has been CE approved for Major Depressive Disorder (MDD) since 2011.

"These new CE approvals are based on the dedicated clinical TMS research studies conducted at multiple renowned research institutions," states Senior Scientist Claus Mathiesen, PhD, MagVenture A/S, further adding: "We believe the CE approvals have the potential of becoming a true game changer for the clinical application of TMS therapy."

TMS Therapy is an advanced, outpatient neuromodulation technology that uses magnetic pulses to stimulate the affected areas in the brain.

For addiction, a pilot study conducted by an Italian research team at Novella Fronda Foundation demonstrated a 69% effect for the TMS group and 19% for the control group receiving the standard of care treatment¹. These initial findings were followed up by an observational study².



For OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group³. For depression, the world's largest randomized controlled study in TMS to date – comprising 414 patients – showed a response rate of 49% and a remission rate of 32% for those receiving theta burst magnetic stimulation⁴. In addition, with this newly approved clinical benefit, TMS has also proven effective in treating the symptoms of anxiety in patients with depression with a response rate of 39% and remission rate of 23%, respectively⁵.

"Expanding our therapeutic TMS indications is the core mission of MagVenture and we cannot wait to bring these new treatment options to the market with the potential to provide help for millions of people affected by these disorders," concludes Claus Mathiesen.

MagVenture is a Danish medical device company specializing in noninvasive magnetic stimulation systems for the treatment of mental disorders and addiction, as well as neuroscience research. MagVenture was the first TMS company to receive CE approval for TMS therapy for MDD in 2011 and this treatment is now offered at clinics around Europe and worldwide.

MagVenture's TMS solutions are also used extensively by brain researchers for a large number of applications and purposes, as well as in clinical research trials where researchers seek to pave the way for new treatments. MagVenture has subsidiaries in Germany, the UK, the USA, and Brazil, and is represented in more than 55 countries worldwide.





MagVenture TMS Therapy® - CE approvals

"Treatment of psychoactive substance use disorder (PSUD) in adult patients."

"As an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD)."

"Treatment of Major Depressive Disorder (MDD) in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode."

MagVenture TMS Therapy® – clinical benefit

For subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.

References

¹Terraneo et al., 2016, European Neuropsychopharmacology: Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study.

²Madeo et al., 2020: Long-Term Outcome of Repetitive Transcranial Magnetic Stimulation in a Large Cohort of Patients With Cocaine-Use Disorder: An Observational Study.

³At one-month follow-up:

Carmi et al., 2018, Am J Psychiatry: Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder.

⁴Blumberger et al., 2018, The Lancet: Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial

⁵Clarke et al., 2019, Journal of Affective Disorders: Efficacy of repetitive transcranial magnetic stimulation in the treatment of depression with comorbid anxiety disorders.

